Evidence method
Level · gp.fundamentals.capex_revenue_ratio
9.87% · OPTIONAL · VALID
GROSSPATTERN / FUNDAMENTAL STATE / POINT IN TIME
ALNY · Sep 30, 2020
ALNYLAM PHARMACEUTICALS, INC.. A multidimensional configuration derived from the filing available at this observation—never a composite score or recommendation.
STATE CAPABILITYLEVEL 3[email protected]
Inspectable configuration
State dimensions
Filing0001178670-20-000019General Corporate
Evidence method
Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue
-87.66% · OPTIONAL · VALID
Evidence method
Yoy · gp.fundamentals.revenue
79.63% · CORE · NOT_ENOUGH_HISTORY
Evidence method
Level · gp.fundamentals.inventory_revenue_ratio
53.19% · OPTIONAL · VALID
Evidence method
Level · gp.fundamentals.gross_margin
82.68% · CORE · VALID
Evidence method
Level · gp.fundamentals.operating_margin
-178.94% · CORE · VALID
Evidence method
Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue
128.55% · OPTIONAL · VALID
Evidence method
Level · gp.fundamentals.sbc_revenue_ratio
29.61% · OPTIONAL · VALID
As-filed lineage
Fundamental state history
Each observation is tied to the filing and facts available at that report date. Amendments remain separate.
History31 statesSelf-history eligible
Jun 30, 20218/9 normalizedLevel 3Sep 30, 20218/9 normalizedLevel 3Dec 31, 20218/8 normalizedLevel 3Mar 31, 20228/9 normalizedLevel 3Jun 30, 20228/9 normalizedLevel 3Sep 30, 20228/8 normalizedLevel 3Dec 31, 20228/8 normalizedLevel 3Mar 31, 20238/8 normalizedLevel 3Jun 30, 20238/8 normalizedLevel 3Sep 30, 20238/8 normalizedLevel 3Dec 31, 20238/8 normalizedLevel 3Mar 31, 20248/8 normalizedLevel 3Jun 30, 20248/8 normalizedLevel 3Sep 30, 20248/8 normalizedLevel 3Dec 31, 20248/8 normalizedLevel 3Mar 31, 20258/8 normalizedLevel 3Jun 30, 20258/8 normalizedLevel 3Sep 30, 20258/8 normalizedLevel 3Dec 31, 20258/8 normalizedLevel 3Jun 30, 20266/6 normalizedLevel 4
Period transition
What moved in the state?
- Previous
- 16.02%
- Current
- 9.87%
- Delta
- -6.16%
- Previous
- -130.17%
- Current
- -87.66%
- Delta
- 42.51%
- Previous
- 132.50%
- Current
- 79.63%
- Delta
- -52.87%
- Previous
- 74.47%
- Current
- 53.19%
- Delta
- -21.28%
- Previous
- 80.83%
- Current
- 82.68%
- Delta
- 1.85%
- Previous
- -191.28%
- Current
- -178.94%
- Delta
- 12.34%
- Previous
- 149.09%
- Current
- 128.55%
- Delta
- -20.54%
- Previous
- 32.47%
- Current
- 29.61%
- Delta
- -2.86%
Self-history only
Previous similar states
Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.
Not enough compatible prior states for a transparent self-history match.
Research Graph
Related governed research
Transitioned To · ALNY Fundamental State →Analogous To · ALNY state analogue 1 →Has State · ALNYLAM PHARMACEUTICALS, INC. →Transitioned To · ALNY Fundamental State →Transitioned To · ALNY CAPEX_INTENSITY_DECREASED →Transitioned To · ALNY CASH_GENERATION_INCREASED →Transitioned To · ALNY GROWTH_DECREASED →Transitioned To · ALNY INVENTORY_PRESSURE_DECREASED →Transitioned To · ALNY MARGIN_INCREASED →Transitioned To · ALNY PROFITABILITY_INCREASED →Transitioned To · ALNY R_AND_D_INTENSITY_DECREASED →Transitioned To · ALNY SBC_INTENSITY_DECREASED →
Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.